Cargando…
Considerations for the US health-system pharmacist in a world of biosimilars
As numerous biosimilar products are forecast to enter the US market in the coming years, health-system pharmacists will be faced with novel challenges while incorporating them into clinical practice. The current regulatory approval framework and guidance from the US Food and Drug Administration do n...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048155/ https://www.ncbi.nlm.nih.gov/pubmed/32158487 http://dx.doi.org/10.7573/dic.2019-12-1 |
_version_ | 1783502251855183872 |
---|---|
author | Zlatkus, Andrea Bixby, Todd Goyal, Kavitha |
author_facet | Zlatkus, Andrea Bixby, Todd Goyal, Kavitha |
author_sort | Zlatkus, Andrea |
collection | PubMed |
description | As numerous biosimilar products are forecast to enter the US market in the coming years, health-system pharmacists will be faced with novel challenges while incorporating them into clinical practice. The current regulatory approval framework and guidance from the US Food and Drug Administration do not address many real-world scenarios that pharmacists will encounter. We provide an overview of the evolving healthcare landscape shaped by the entry of multiple biosimilars, including for a given reference product, and their impact on the health-system pharmacist with respect to formulary assessment, implementation, and education of various health-system stakeholders, including patients. |
format | Online Article Text |
id | pubmed-7048155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioExcel Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-70481552020-03-10 Considerations for the US health-system pharmacist in a world of biosimilars Zlatkus, Andrea Bixby, Todd Goyal, Kavitha Drugs Context Editorial As numerous biosimilar products are forecast to enter the US market in the coming years, health-system pharmacists will be faced with novel challenges while incorporating them into clinical practice. The current regulatory approval framework and guidance from the US Food and Drug Administration do not address many real-world scenarios that pharmacists will encounter. We provide an overview of the evolving healthcare landscape shaped by the entry of multiple biosimilars, including for a given reference product, and their impact on the health-system pharmacist with respect to formulary assessment, implementation, and education of various health-system stakeholders, including patients. BioExcel Publishing Ltd 2020-02-25 /pmc/articles/PMC7048155/ /pubmed/32158487 http://dx.doi.org/10.7573/dic.2019-12-1 Text en Copyright © 2020 Zlatkus A, Bixby T, Goyal K. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission. |
spellingShingle | Editorial Zlatkus, Andrea Bixby, Todd Goyal, Kavitha Considerations for the US health-system pharmacist in a world of biosimilars |
title | Considerations for the US health-system pharmacist in a world of biosimilars |
title_full | Considerations for the US health-system pharmacist in a world of biosimilars |
title_fullStr | Considerations for the US health-system pharmacist in a world of biosimilars |
title_full_unstemmed | Considerations for the US health-system pharmacist in a world of biosimilars |
title_short | Considerations for the US health-system pharmacist in a world of biosimilars |
title_sort | considerations for the us health-system pharmacist in a world of biosimilars |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048155/ https://www.ncbi.nlm.nih.gov/pubmed/32158487 http://dx.doi.org/10.7573/dic.2019-12-1 |
work_keys_str_mv | AT zlatkusandrea considerationsfortheushealthsystempharmacistinaworldofbiosimilars AT bixbytodd considerationsfortheushealthsystempharmacistinaworldofbiosimilars AT goyalkavitha considerationsfortheushealthsystempharmacistinaworldofbiosimilars |